GENESIS Pharma, one of the leading regional biopharma companies focused on the commercialisation of innovative medicines in Europe, on June 10th, announced the expansion of its longstanding commercial partnership with Alnylam Pharmaceuticals, Inc., one of the leading RNAi therapeutics companies. The extended agreement broadens the geographical reach of the collaboration to include four Nordic markets -Denmark, Finland, Norway, and Sweden- alongside the thirteen markets in Southeast Europe already within the scope of the partnership. GENESIS Pharma shall commercialise a portfolio of RNAi therapeutics for serious cardiomyopathy conditions and rare genetic diseases across this expanded territory.
The partnership, established in 2019 for Southeast Europe, has progressively evolved to encompass a broader portfolio and geographic footprint, covering Greece, Cyprus, Bulgaria, Romania, Slovenia, Croatia, Serbia, Bosnia and Herzegovina, Albania, the Republic of North Macedonia, Montenegro, Malta, and Kosovo. This latest strategic expansion reinforces both companies’ shared commitment to improving patient access to innovative therapies across Europe, particularly in regions where unmet medical needs remain significant.
Norton Oliveira, Senior Vice-President and Head of Partner and Emerging Markets at Alnylam Pharmaceuticals, stated: “We are proud of our strong and established partnership with GENESIS Pharma and are delighted to broaden this across the Nordic region. Our commitment is to deliver transformational impact for patients across the world. By working alongside GENESIS Pharma, we can continue to address the needs of even more patients and their families, enabling them to benefit from Alnylam’s innovative RNAi therapeutics.”
Constantinos Evripides, Managing Director of GENESIS Pharma, stated: “Since 2019, we have been working closely with Alnylam to ensure patient access across Southeast Europe. The expansion in the Nordic countries marks a significant milestone in our partnership and reflects our ongoing efforts to strengthen our European footprint, building on our three-decade legacy and commitment to biotechnology. By combining Alnylam’s pioneering science with our strong regional expertise in bringing innovation closer to patients, we continue to expand our reach and enhance the value we deliver across healthcare systems. We are honoured by the trust Alnylam has placed in our company and our people.”
More related news:
AusperBio secures USD 37Mln in series A financing
Polpharma Biologics and Tuteur Sign Biosimilar Licensing Deal
